2004

2004 INTERCEPT Conference Abstracts

 

Jump to Conference
ASBMT ISBT AABB
ISHEID DGTI ASH

 

American Society for Blood and Marrow Transplantation (ASBMT)
February 2004 | Orlando, Florida, USA

  • Vesole D, Stadtmauer E, Goodnough LT et al for the SPRINT Study Group. Source of donor stem cells impacts incidence of bleeding and platelet and RBC transfusion requirements during stem cell transplantation (SCT): results of the phase III SPRINT trial of INTERCEPT pathogen-inactivated platelets.

International Symposium on HIV & Emerging Infectious Diseases (ISHEID)
June 2004 |
Toulon, France

  • Sawyer L, Dupuis K, Sampson-Johannes A et al. Helinx technology inactivates high titers of SARS-CoV, WNV and Vaccinia in platelet concentrates.

International Society of Blood Transfusion (ISBT)
July 2004 | Edinburgh, Scotland

  • Conlan MG, Corash L, Flament J et al for the euroSPRITE, SPRINT and STEP Study Groups. INTERCEPT Platelets & Plasma do not result in neoantigenicity: results of 7 phase 3 clinical trials.
     
  • Donnelly B, Sawyer L, Lin L. Similar in vitro function and bacterial inactivation, leukoreduced (Lr) vs non-Lr INTERCEPT Platelets.
     
  • Dupuis K, Sampson-Johannes A, Bernard K. Helinx® technology inactivates high titers of SARS-CoV, WNV and Vaccinia in INTERCEPT Platelets.
     
  • Sullivan T, McCullough T. Assessment of safety for the INTERCEPT® Blood System for platelets in neonatal preclinical model.

Deutschen Gessellschaft für Transfusionsmedizin und Immunhämatologie e.V. (DGTI)
September 2004 | Mannheim, Germany   

  • Chen C, Donnelly B, Blair A et al. INTERCEPT Platelets from Haemonetics MCS+ ® and Cobe Spectra demonstrate pathogen inactivation, retain function, and meet Council of Europe standards.
     
  • Chen D, Donnelly B, Taga T et al. INTERCEPT Platelets from Trima collection system retain function, demonstrate inactivation of key pathogens, and meet Council of Europe standards.
     
  • Dupuis K, Sampson-Johannes A, Bernard K et al. Helinx® technology inactivates high titers of SARS-CoV, WNV and Vaccinia in platelet concentrates.

American Association of Blood Banks (AABB)
October 2004 | Baltimore, Maryland, USA 

  • Hanson D, Dupuis K, Sawyer L. Inactivation of Parvovirus B19 in platelets by Helinx® technology.

American Society of Hematology (ASH)
December 2004 | San Diego, California, USA 

  • Benoit Y, Van Haute I, Vandecruys E et al. Safety and efficacy of pathogen-inactivated platelets transfused in routine use to pediatric patients: an interim report.
     
  • Moeremans K, Warie H, Annemans L et al. Assessment of the economic value of the INTERCEPT Blood System for platelets in Belgium.
     
  • Osselaer JC, Doyen D, Sonet A et al. Routine use of platelet components prepared with photochemical treatment (INTERCEPT Platelets): impact on clinical outcomes and costs.
Untitled Document